CYP11A1 is a mitochondrial cytochrome P450 monooxygenase that catalyzes the first and rate-limiting step of steroidogenesis, converting cholesterol to pregnenolone through sequential hydroxylation at C22 and C20 positions followed by side-chain cleavage 1. This pregnenolone serves as the precursor for synthesis of all steroid hormones including glucocorticoids and androgens 2. The enzyme transfers electrons from NADPH via the mitochondrial electron transfer system comprising FDXR and FDX1/FDX2 proteins 1. Beyond cholesterol, CYP11A1 metabolizes alternative substrates including 7-dehydrocholesterol, plant sterols, and vitamin D compounds, with emerging evidence supporting in vivo production of bioactive metabolites 3. CYP11A1 expression is tissue-selective, regulated by transcription factors including SF-1 in steroidogenic tissues 2, and its localization to mitochondrial cristae influences mitochondrial morphology 4. Dysregulation of CYP11A1 contributes to polycystic ovary syndrome through excessive androgen production, and artemisinin compounds ameliorate this by promoting CYP11A1 degradation via LONP1 interaction 5. CYP11A1 mutations cause congenital adrenal insufficiency with sex reversal. Emerging research suggests CYP11A1-derived vitamin D metabolites may have immunomodulatory potential in COVID-19 6, though the physiological significance of alternative substrate metabolism requires further investigation.